News
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
August 13, 2018
Recent Corporate Highlights: Closed initial public offering of common stock on July 19, 2018, generating $63.9 million in gross proceeds Expanded pipeline with two additional clinical-stage assets...
-
July 31, 2018- Provention strengthens its strategic platform in type 1 diabetes (T1D) interception and prevention
Provention Bio, Inc. (Nasdaq:PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced today the appointment of Mark Rigby, MD,...
-
July 19, 2018
Provention Bio, Inc. (Nasdaq:PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced today the closing of its initial public...
-
May 09, 2018-- Provention acquires PRV-031 (teplizumab) and plans to initiate pivotal Phase 3 clinical trial to intercept early-onset type 1 diabetes, a pediatric orphan indication
Provention Bio, Inc., a clinical-stage biopharmaceutical company dedicated to sourcing, developing and commercializing novel therapeutics aimed at intercepting and preventing immune-mediated...
-
May 07, 2018- Coxsackievirus B appears to be an important trigger for type 1 diabetes
Provention Bio, Inc. (Provention), a clinical stage biopharmaceutical company dedicated to sourcing, developing and commercializing novel therapeutics aimed at intercepting and preventing...
-
September 28, 2017-- Andrew Drechsler Named Chief Financial Officer
Provention Bio, Inc., a clinical-stage biopharmaceutical company dedicated to sourcing, developing and commercializing novel therapeutics aimed at intercepting and preventing immune-mediated...
-
September 21, 2017- Provention to initiate Phase 2a Study of PRV-6527 (JNJ-40346527) in patients with moderate to severe Crohn's disease
Provention Bio, Inc., a clinical stage biopharmaceutical company dedicated to sourcing, developing and commercializing novel therapeutics aimed at intercepting and preventing immune-mediated...
-
July 18, 2017- Enterovirus vaccine platform in-licensed from Vactech Oy will be developed to "pre-empt" type 1 diabetes by targeting coxsackievirus B infection
Provention Bio, Inc., a clinical stage biopharmaceutical company dedicated to sourcing, developing and commercializing novel therapeutics aimed at intercepting and preventing immune-mediated...
-
July 11, 2017Accomplished Biopharmaceutical and Drug Development Executive to Spearhead Provention's Vision of Intercepting and Preventing Immune-mediated Disease
Provention Bio, Inc., a clinical-stage biopharmaceutical company dedicated to sourcing, developing and commercializing novel therapeutics aimed at intercepting and preventing immune-mediated...
-
June 26, 2017Industry innovators, Francisco Leon, MD, Ph.D. and Ashleigh Palmer, cofound newly established company
Provention Bio, Inc., a recently founded clinical-stage biopharmaceutical company dedicated to sourcing, developing and commercializing novel therapeutics aimed at intercepting and preventing...